Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty ...
In an interview, Scholar Rock's chief medical officer talks about benefits seen in clinical trials of its muscle-targeted SMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback